SAT-655 Comparative Analysis of Glucagon Receptor Agonists vs Resmetirom in MASLD and MASH:Network Meta-Analysis of Clinical Trials

J Endocr Soc · 2025 · PMC12546058

Europe PMC

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

showed a trendp = 0.056so close (0.05 < p ≤ 0.1)

SAE risk was not significantly elevated for Resmetirom (RR: 1.11, 95% CI: [0.77; 1.59], p = 0.58), but GRAs showed a trend toward higher SAE rates (RR: 2.38, 95% CI: [0.98; 5.82], p = 0.056).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.